S K Seo1, Z Gedrimaite2, A Paskovaty3, K Seier4, S Morjaria2, N Cohen3, E Riedel4, Y W Tang5, N E Babady6. 1. Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: seos@mskcc.org. 2. Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA. 6. Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVE: To evaluate the impact of rapidly identifying coagulase-negative staphylococci (CoNS) from positive blood cultures combined with an established antimicrobial stewardship (AS) programme at a tertiary cancer centre. METHODS: We compared cancer patients ≥18 years old who between 01/1/13 and 12/31/13 had one or more positive CoNS blood culture(s) identified by Staphylococcus QuickFISH® (a peptide nucleic acid fluorescence in situ hybridization assay) with cancer patients ≥18 years old who had CoNS identified by standard microbiological techniques between 01/01/11 and 12/31/11 (baseline). Positive blood culture results were reported to the clinician by microbiology staff; restricted antibiotics (e.g., vancomycin) required approval by the AS team. RESULTS: There were 196 baseline and 103 QuickFISH patients. Faster median time to organism identification (33 (IQR 27-46) versus 49 (IQR 39-63) hours, p < 0.001), more vancomycin avoidance (51/103 (50%) versus 60/196 (31%), p 0.002), shorter median antibiotic duration (1 (IQR 0-3) versus 2 (IQR 0-6) days, p 0.019), fewer central venous catheter (CVC) removals (14/78 (18%) versus 57/160 (36%), p 0.004), and reduced vancomycin level monitoring (16/52 (31%) versus 71/136 (52%), p 0.009) were observed in the QuickFISH group. QuickFISH implementation was predictive of a lower likelihood of antibiotic therapy prescription (OR 0.35, 95%CI 0.20-0.62, p < 0.001). Prior transplant (RR 1.47, 95%CI 1.13-1.92, p 0.004), neutropenia (RR 1.47, 95%CI 1.09-1.99, p 0.012), multiple positive blood cultures (RR 4.23, 95%CI 3.23-5.54, p < 0.001), and CVC (RR 1.60, 95%CI 1.02-2.53, p 0.043) were independent factors for antibiotic duration. CONCLUSIONS: QuickFISH implementation plus AS support leads to greater avoidance of vancomycin therapy and improved resource utilization in cancer patients with CoNS blood cultures.
OBJECTIVE: To evaluate the impact of rapidly identifying coagulase-negative staphylococci (CoNS) from positive blood cultures combined with an established antimicrobial stewardship (AS) programme at a tertiary cancer centre. METHODS: We compared cancerpatients ≥18 years old who between 01/1/13 and 12/31/13 had one or more positive CoNS blood culture(s) identified by Staphylococcus QuickFISH® (a peptide nucleic acid fluorescence in situ hybridization assay) with cancerpatients ≥18 years old who had CoNS identified by standard microbiological techniques between 01/01/11 and 12/31/11 (baseline). Positive blood culture results were reported to the clinician by microbiology staff; restricted antibiotics (e.g., vancomycin) required approval by the AS team. RESULTS: There were 196 baseline and 103 QuickFISH patients. Faster median time to organism identification (33 (IQR 27-46) versus 49 (IQR 39-63) hours, p < 0.001), more vancomycin avoidance (51/103 (50%) versus 60/196 (31%), p 0.002), shorter median antibiotic duration (1 (IQR 0-3) versus 2 (IQR 0-6) days, p 0.019), fewer central venous catheter (CVC) removals (14/78 (18%) versus 57/160 (36%), p 0.004), and reduced vancomycin level monitoring (16/52 (31%) versus 71/136 (52%), p 0.009) were observed in the QuickFISH group. QuickFISH implementation was predictive of a lower likelihood of antibiotic therapy prescription (OR 0.35, 95%CI 0.20-0.62, p < 0.001). Prior transplant (RR 1.47, 95%CI 1.13-1.92, p 0.004), neutropenia (RR 1.47, 95%CI 1.09-1.99, p 0.012), multiple positive blood cultures (RR 4.23, 95%CI 3.23-5.54, p < 0.001), and CVC (RR 1.60, 95%CI 1.02-2.53, p 0.043) were independent factors for antibiotic duration. CONCLUSIONS: QuickFISH implementation plus AS support leads to greater avoidance of vancomycin therapy and improved resource utilization in cancerpatients with CoNS blood cultures.
Authors: Graeme N Forrest; Sanjay Mehta; Elizabeth Weekes; Durry P Lincalis; Jennifer K Johnson; Richard A Venezia Journal: J Antimicrob Chemother Date: 2006-04-24 Impact factor: 5.790
Authors: Melissa K Deck; Erica S Anderson; Rebecca J Buckner; Georgia Colasante; James M Coull; Benjamin Crystal; Phyllis Della Latta; Martin Fuchs; Deanna Fuller; Will Harris; Kevin Hazen; Lisa L Klimas; Daniel Lindao; Michelle C Meltzer; Margie Morgan; Janeen Shepard; Sharon Stevens; Fann Wu; Mark J Fiandaca Journal: J Clin Microbiol Date: 2012-04-04 Impact factor: 5.948
Authors: Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia Journal: Antimicrob Agents Chemother Date: 2008-07-28 Impact factor: 5.191
Authors: Charles A Schiffer; Pamela B Mangu; James C Wade; Dawn Camp-Sorrell; Diane G Cope; Bassel F El-Rayes; Mark Gorman; Jennifer Ligibel; Paul Mansfield; Mark Levine Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Emily L Heil; Lindsay M Daniels; Dustin M Long; Kyle G Rodino; David J Weber; Melissa B Miller Journal: Am J Health Syst Pharm Date: 2012-11-01 Impact factor: 2.637